Research programme: analgesics - Cenomed BioSciencesAlternative Names: CM-2,359; CM-2,397
Latest Information Update: 31 Aug 2007
At a glance
- Originator Cenomed BioSciences LLC
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 31 Aug 2007 No development reported - Preclinical for Pain in USA (unspecified route)
- 01 Feb 2005 Preclinical trials in Pain in USA (unspecified route)